Ovarian malignancy risk

Alphabetical Test listing

Ovarian malignancy risk-994

Ovarian malignancy risk

The ROMA® (Risk of Ovarian Malignancy Algorithm) calculation combines the results of the Roche Elecsys HE4 assay, Elecsys CA 125 II assay and menopausal status into a numerical score (Roche). The ROMA value is intended to aid in assessing whether a premenopausal or postmenopausal woman who presents with an ovarian adnexal mass is at high or low likelihood of finding malignancy on surgery. ROMA Calculation is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned and not yet referred to an oncologist. ROMA values must be interpreted in conjunction with an independent clinical and radiological assessment. The test is not intended as a screening or stand-alone diagnostic assay.


This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of Biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R).

It is recommended to ask all patients who may be indicated for this test about Biotin supplementation. Patients should be cautioned to stop Biotin consumption at least 72 hours prior to the collection of a sample.

1.75 mL
1.0 mL
Submission of the minimum volume does not allow for repeat testing

Immediatley following collection, mix sample by gently inverting 5 times

  1. Allow sample to clot for a minimum of 30 minutes
  2. Spin within two (2) hours of sample collection

Gold serum separator (SST) tube

  1. Allow sample to clot
  2. Spin
  3. Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp) labelled as "serum" within two (2) hours of sample collection

Refrigerated (preferred) - 14 days

Ambient - 14 days

  • Gross hemolysis
LabCorp Burlington (140045): R-NX
Mo - Fr
1 - 3 days

Electrochemiluminescence Immunoassay (ECLIA)


An interpretive report will be provided

Biotin supplement interference - see patient preparation
Result 10334-1